Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329294 | 0.83 | CA2 (0.71) | CA2CA1CA9 | |
| SCHEMBL329449 | 0.82 | CA2 (0.69) | CA2CA1CA9 | |
| SCHEMBL329450 | 0.80 | CA2 (0.67) | CA2CA1CA9 | |
| SCHEMBL743918 | 0.80 | CA2 (0.67) | CA2CA1CA9 | |
| SCHEMBL12157405 | 0.80 | CA2 (0.67) | CA2CA1CA9 | |
| SCHEMBL25119616 | 0.80 | CA2 (0.67) | CA2CA1CA9 | |
| Hydrochloric Acid SCHEMBL27538000 | 0.78 | CA2 (0.65) | CA2CA1CA9 | |
| SCHEMBL1416155 | 0.78 | CA2 (0.65) | CA2CA1CA9 | |
| Naphthalene SCHEMBL11617631 | 0.77 | CA2 (0.62) | CA2CA1CA9 | |
| SCHEMBL10367944 | 0.77 | CA2 (1.00) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103108864-A | Arylsulfonamides for treatment of CNS disorders | ADAMED SP ZOO | 2013-05-15 | — | — | CN | claimed |
| EP-2493459-A1 | OCULAR DRUG DELIVERY DEVICES | Aton Pharma, Inc. (US) | 2012-09-05 | — | — | EP | claimed |
| WO-2011022207-A1 | BIS-SULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-24 | — | — | WO | claimed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-1325920-B1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVES | TOA EIYO LTD (JP) | 2010-08-25 | — | — | EP | claimed |
| EP-1486494-B1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVE | TOA EIYO LTD (JP) | 2010-07-14 | — | — | EP | claimed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | claimed |
| EP-1960343-A2 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-27 | — | — | EP | claimed |
| US-7399781-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2008-07-15 | — | — | US | claimed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | claimed |
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | TEIJIN PHARMA LIMITED (JP) | 2007-02-08 | — | — | US | claimed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| WO-2006108709-A1 | 3-SULFONYLAMINO-PYRROLIDINE-2-ONE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | claimed |
| US-7071220-B2 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-07-04 | — | — | US | claimed |
| EP-1666067-A1 | DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT | Teijin Pharma Limited (JP) | 2006-06-07 | — | — | EP | claimed |
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. (JP) | 2006-06-01 | — | — | US | claimed |
| EP-1486494-A1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVE | TOA EIYO LTD. (JP) | 2004-12-15 | — | — | EP | claimed |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | TOA EIYO LTD. | 2003-12-11 | — | — | US | claimed |
| EP-1325920-A1 | N-SUBSTITUTED BENZOTHIOPHENESULFONAMIDE DERIVATIVES | TOA EIYO LTD. (JP) | 2003-07-09 | — | — | EP | claimed |
| EP-0079683-B1 | HERBICIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116408-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | CA2 128/4885CA1 1121/4885CA9 454/4885 |
| US-20030229126-A1 | N-substituted benzothiophenesulfonamide derivatives | ECE1, ECE2, CMA1 | CA2 128/4885CA1 1121/4885CA9 454/4885 |
| US-20070032466-A1 | Drug containing chymase inhibitor as the active ingredient | REN, SERPINB1, CMA1 | CA2 1323/4885CA1 2471/4885CA9 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.